(ANSA) - ROME, SEPTEMBER 23 - The phase 3 test of the vaccine candidate against Covid-19 from Janssen, Johnson & Johnson, based on a single dose, starts in the United States. 60,000 volunteers are expected to be recruited at 215 centers in the US. This was announced today by Anthony Fauci, director general of the American Institute for Infectious Diseases (Niaid), which is part of the National Institutes of Health (Nih), and the American body for research and biomedical Barda (Biomedical Advanced Research and Development Authority).
It is the fourth phase 3 test underway in the US after those of Modern, AstraZeneca and Pfizer, thanks to a race never seen before in the issuing of authorizations. (HANDLE).